Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10850394 | 0.86 | SMN1; SMN2 (0.76) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| Bromide SCHEMBL3850911 | 0.85 | SMN1; SMN2 (0.74) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| Bromide SCHEMBL3845988 | 0.85 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| SCHEMBL10531134 | 0.84 | SMN1; SMN2 (0.74) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| Bromide SCHEMBL3849689 | 0.83 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| SCHEMBL20527600 | 0.83 | SMN1; SMN2 (0.97) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| SCHEMBL20527637 | 0.83 | LMNA (0.72) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| Bromide SCHEMBL3853189 | 0.82 | LMNA (0.71) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| SCHEMBL20527661 | 0.82 | LMNA (0.59) | LMNASMN1; SMN2KMT2AMEN1RECQL | |
| Bromide SCHEMBL3853584 | 0.81 | SMN1; SMN2 (0.57) | LMNASMN1; SMN2KMT2AMEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1213282-A1 | Substituted imidazolium salts and their use for the inhibition of protein ageing. | ALTEON Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2018149672-A1 | TWO-COMPONENT POLYURETHANE COMPOSITION COMPRISING A LATENT CATALYST | HENKEL AG & CO. KGAA (DE) | 2018-08-23 | — | — | WO | disclosed |
| EP-3363840-A1 | TWO-COMPONENT POLYURETHANE COMPOSITION COMPRISING A LATENT CATALYST | Henkel AG & Co. KGaA (DE) | 2018-08-22 | — | — | EP | disclosed |
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1305024-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | ALTEON, INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1305024-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | Alteon, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002053158-A1 | METHOD FOR TREATING GLAUCOMA IB | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| EP-1213282-A1 | Substituted imidazolium salts and their use for the inhibition of protein ageing. | ALTEON Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-0920418-A1 | SUBSTITUTED IMIDAZOLIUM SALTS AND THEIR USE FOR THE INHIBITION OF PROTEIN AGEING | ALTEON, INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1997042175-A1 | SUBSTITUTED IMIDAZOLIUM SALTS AND THEIR USE FOR THE INHIBITION OF PROTEIN AGEING | ALTEON INC. (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | LMNA 2101/4885SMN1; SMN2 3940/4885KMT2A 4535/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | LMNA 1032/4885SMN1; SMN2 549/4885KMT2A 4545/4885 |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, COL2A1 | LMNA 825/4885SMN1; SMN2 204/4885KMT2A 4051/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | LMNA 1911/4885SMN1; SMN2 1693/4885KMT2A 4493/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | LMNA 685/4885SMN1; SMN2 295/4885KMT2A 4326/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | LMNA 473/4885SMN1; SMN2 306/4885KMT2A 4075/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | LMNA 1815/4885SMN1; SMN2 2173/4885KMT2A 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.